PREVALENCE AND RISK FACTORS OF PROLONGED QTc INTERVAL IN HIV-INFECTED PATIENTS
DOI:
https://doi.org/10.11603/1681-2727.2015.4.5513Abstract
SUMMARY. 136 patients with HIV/AIDS were under observation. It has been found cardiotropic effect of human immunodeficiency virus, and thus significantly more diverse manifestations changes recorded bioelectrical activity of the heart due to the progression of HIV and on the background of a high viral load of HIV RNA and low immune defense.
The risk of abnormal QTc interval statistically higher among HIV-positive female patients, it grew up in the deepening of immunodeficiency and duration of HIV infection (over 5 years). The increase in the electrical ventricular systole also recorded significantly more frequently in HIV-infected patients with Right Bundle Branch Block and in patients with ischemic changes in the myocardium. Patients with QTc interval prolongation compared with patients with normal duration of this interval had a significantly higher incidence of co-infection with hepatitis C.
HIV-infected patients are at significant risk of QT prolongation due to medications, but the relationship between the use of protease inhibitors and prolongation QTs still negligible.
Key words: HIV-infection, cardiovascular disease, interval QT, QTc prolongation.
References
Література
Asymptomatic myocardial ischaemia in HIV-infected adults / [A. Carr, B. Grund, J. Neuhaus et al.] // AIDS. – 2008. – Vol. 22, N 2. – R. 257-267.
Ischemic heart disease in HIV-infected and HIV uninfected individuals: a population-based cohort study / [N. Obel, H.F. Thomsen, G. Kronborg et al.] // Clin. Infect. Dis. – 2007. – Vol. 44. – R. 1625-1631.
Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City / J.E. Sackoff, D.B. Hanna, M.R. Pfeiffer, L.V. Torian // Ann. Intern. Med. – 2006. – Vol. 145. – R. 397-406.
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study / [F.J.Jr. Palella, R.K. Baker, A.C. Moorman et al.] // J. Acquir. Immune Defic. Syndr. – 2006. – Vol. 43. – R. 27-34.
Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors / F. Boccara // AIDS. – 2008. – Vol. 22. – S19-S26.
Prolonged QTc interval and risk of sudden cardiac death in a population of older adults / [S.M. Straus, J.A. Kors, M.L. De Bruin et al.] // J. Am. Coll. Cardiol. – 2006. – Vol. 47. – R. 362-367.
Chugh S.S. Determinants of Prolonged QT Interval and Their Contribution to Sudden Death Risk in Coronary Artery Disease. The Oregon Sudden Unexpected Death Study / S.S. Chugh, K. Reinier, T. Singh // Circulation. – 2009. – Vol. 119. – R. 663-670.
Liew R. Electrocardiogram-Based Predictors of Sudden Cardiac Death in Patients With Coronary Artery Disease/ R. Liew // Clin. Cardiol. – 2011. – Vol. 34, N 8. – R. 466-473.
Electrocardiographic QT interval and mortality: a metaanalysis / [Y. Zhang, W.S. Post, E. Blasco-Colmenares et al.] // Epidemiology. – 2011. – Vol. 22, N 5. – R. 660-670.
QT-Interval Duration and Mortality Rate. Results From the Third National Health and Nutrition Examination Survey / [Y. Zhang, W.S. Post, D. Dalal et al.] // Arch. Intern. Med. – 2011. – Vol. 171, N 19. – R. 1727-1733.
Sauer A.J. Clinical and Genetic Determinants of Torsade de Pointes Risk / A.J. Sauer, C. Newton-Cheh // Circulation. – 2012. – Vol. 125. – R. 1684-1694.
Van Noord C. Drug- and non-drug-associated QT interval prolongation / C. van Noord, M. Eijgelsheim, B.H.Ch. Stricker // Br. J. Clin. Pharmacology. – 2010. – Vol. 70, N 1. – R. 16-23.
Furman N.V. Klynycheskoe znachenye udlynenyia yntervalov QT y QTc na fone pryёma lekarstvennykh preparatov / N.V. Furman, S.S. Shmatova // Ratsyonalnaia farmakoterapyia v kardyolohyy. – 2013. – T. 9, № 3. – S. 311-315.
Nachimuthu S. Drug-induced QT Interval Prolongation Mechanisms and Clinical Management / S. Nachimuthu, M.D. Assar, J.M. Schussler // Ther. Adv. Drug. Safe. – 2012. – Vol. 5, N 3. – R. 241-253.
Behr E.R. Drug-induced arrhythmia: pharmacogenomic prescribing? / E.R. Behr, D. Roden // Eur. Heart J. – 2013. – Vol. 34. – R. 89-95.
Heist E.K. Drug-Induced Arrhythmia / E.K. Heist, J.N. Ruskin // Circulation. – 2010. – Vol. 122. – R. 1426-1435.
Kannankeril P. Drug-Induced Long QT Syndrome / P. Kannankeril, D.M. Roden, D. Darbar // Pharmacol. Rev. – 2010. – Vol. 62, N 4. – R. 760-781.
A pharmacokinetic – pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human a-ethera-go-go-related inhibition data / [D.M. Jonker, L.A. Kenna, D. Leishman et al.] // Clin. Pharmacol. Ther. – 2005. – Vol. 77. – R. 572-582.
Ageing with HIV: medication use and risk for potential drug-drug interactions / [C. Marzolini, D. Back, R. Weber et al.] // J. Antimicrob. Chemother. – 2011. – Vol. 66. – R. 2107-2111.
Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy / C.D. Miller, R. El-Kholi, J.J. Faragon, T.P. Lodise // Pharmacotherapy. – 2007. – Vol. 27. – R. 1379-1386.
Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens / N. Patel, S. Abdelsayed, M. Veve, C.D. Miller // Ann. Pharmacother. – 2011. – Vol. 45. – R. 317-324.
Ly T. Prolonged QT interval and torsades de pointes associated with atazanavir therapy / T. Ly, M.E. Ruiz // Clin. Infect. Dis. – 2007. – Vol. 44. – R. 67-68.
Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants / [X. Zhang, P. Jordan, L. Cristea et al.] // J. Clin. Pharmacol. – 2012. – Vol. 52. – R. 520-529.
Murashko V.V. Эlektrokardyohrafyia: Uchebn. posobye / V.V. Murashko, A.V. Strutynskyi. – [5-e yzd.]. –M.: MEDpress-ynform, 2001. – 312 s.
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations / [E.Z. Soliman, J.D. Lundgren, M.P. Roediger et al.] // AIDS. – 2011. – Vol. 25. – R. 367-377.
Klinichnyi protokol antyretrovirusnoi terapii VIL-infektsii u doroslykh ta pidlitkiv. – Zatverdzheno nakazom MOZ Ukrainy № 551 vid 12.07.2010 r.: http://mozdocs.kiev.ua/view.php?id=11177.
Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients / [C. Nordin, A. Kohli, S. Beca et al.] // J. Electrocard. – 2006. – Vol. 39, N 2. – R. 199-205.
Prevalence and Risk Factors of Prolonged QTc Interval in HIV-Infected Patients: Results of the HIV-HEART Study / [N. Reinsch, C. Buhr, P. Krings et al.] // HIV Clin. Trials. – 2009. – Vol. 10, N 4. – R. 261-268.
Blockade of HERG channels by HIV protease inhibitors / [B.D. Anson, J.G. Weaver, M.J. Ackerman et al.] // Lancet. – 2005. – Vol. 365. – R. 682-686.
Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients / [R.P. van Heeswijk, M. Bourbeau, I. Seguin et al.] // Br. J. Clin. Pharmacol. – 2005. – Vol. 59. – R. 398-404.
Lopinavir protein binding in vivo through the 12-hour dosing interval / [M. Boffito, P.G. Hoggard, W.E. Lindup et al.] // Ther. Drug Monit. – 2004. – Vol. 26. – R. 35-39.
Sani M.U. QTc interval prolongation in patients with HIV and AIDS / M.U. Sani, B.N. Okeahialam // J. Nation. Med. Assoc. – 2005. – Vol. 97, N 12. – R. 1657-1661.
Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study / [B. Charbit, A. Rosier, D. Bollens et al.] // Br. J. Clin. Pharmacol. – 2008. – Vol. 67, N 1. – R. 76-82.
QTc interval prolongation in HIV-infected patients: a case–control study by 24-hour Holter ECG recording / [A. Fiorentini, N. Petrosillo, A. Di Stefano et al.] // BMC Cardiovascular Disorders. – 2012. – Vol. 12. – R. 124-129.
Frequency of Electrocardiogram Testing Among HIV-Infected Patients at Risk for Medication-Induced QTc Prolongation / [N. Patel, M. Veve, S. Kwon et al.] // HIV Medicine. – 2013. – Vol. 14, N 8. – R. 463-471.
Downloads
Published
How to Cite
Issue
Section
License
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
